Searchable abstracts of presentations at key conferences in endocrinology

ea0029oc4.3 | Pituitary Basic | ICEECE2012

miR-26a targets PRKCD in ACTH pituitary adenoma

Gentilin E. , Tagliati F. , degli Uberti E. , Zatelli M.

MicroRNAs (miRNAs) have several physiological functions, but have been also implicated in human neoplastic initiation and progression. We previously demonstrated that 30 miRNAs are differentially expressed in normal human pituitary as compared to pituitary adenomas. However, the most of miRNAs target genes remain unknown, hindering the understanding of the miRNAs contribute to pituitary tumorigenesis.The aims of this study were to: (i) validate a murine ...

ea0035oc7.1 | IGF-1 and Thyroid Basic | ECE2014

GH induces chemoresistance in human endometrial cancer cell lines involving ERK 1/2 and PKCdelta

Zuolo Giulia , Minoia Mariella , Gentilin Erica , Gagliano Teresa , Tagliati Federico , Zatelli Maria Chiara , Uberti Ettore degli

Background: Surgery is the main therapeutic option for advanced endometrial cancer; however, when disease relapses, chemotherapy is the only option. Chemoresistance is a very common phenomenon in these tumors. We previously demonstrated that GH protects breast cancer cells towards the cytotoxic effects of doxorubicin, inducing chemoresistance. Recent evidences show that endometrial cancer cells secrete GH, stimulating their own growth in an autocrine fashion.<p class="abst...

ea0032p539 | Endocrine tumours and neoplasia | ECE2013

Involvement of PKCβ and PKCδ isoforms in TSH signaling pathway in thyroid cancer cell lines

Mole Daniela , Gentilin Erica , Gagliano Teresa , Tagliati Federico , degli Uberti Ettore , Zatelli Maria Chiara

It is well established that most TSH effects on the thyroid gland, including stimulation of proliferation, thyroid hormone synthesis and expression of thyroid-specific genes, are transmitted mainly by the adenylate cyclise pathway. However, in human follicular cells and in rat FRTL-5 cells, TSH can also stimulate the β-isoforms of PLC that catalyzes the hydrolysis of phosphatidyl-inositol 4,5-phosphate, yielding the second messengers DAG and inositol 1,4,5-phosphate facil...

ea0029oc9.2 | Endocrine Tumours &amp; Translation | ICEECE2012

GH protects breast cancer cells from chemotherapy by blocking cytotoxic-induced apoptosis in estrogen receptor negative breast cancer cells

Minoia M. , Gentilin E. , Mole D. , Tagliati F. , Ambrosio M. , degli Uberti E. , Zatelli M.

Context: GH and insulin-like growth factor (IGF1) play important roles in breast cancer (BC) development. IGF1 has been shown to importantly influence estrogen effects on BC, suggesting that estrogen receptors (ER) may mediate also GH effects. We previously demonstrated that GH and IGF1 protect the ER positive BC-derived MCF7 cell line towards the cytotoxic effects of doxorubicin (D), independently of IGF1.Aim of the study: Evaluate whether this holds tr...

ea0029p800 | Endocrine tumours and neoplasia | ICEECE2012

Effects of mTOR inhibitors in the control of non functioning pituitary adenomas cell growth

Minoia M. , Gentilin E. , Rossi M. , Tagliati F. , degli Uberti E. , Zatelli M.

Introduction: The main therapeutic approach for non functioning pituitary adenomas (NFA) is surgery, since radiotherapy has several important side effects and medical therapy is rarely effective. Therefore, understanding the molecular pathways regulating NFA cell proliferation is crucial for future drug development. We here explore the possible role of mTOR inhibitors, Everolimus and BEZ235 (which also inhibits the PI3 K pathway) on the effects of Insulin-like Growth Factor-1 ...

ea0026p180 | Neuroendocrinology | ECE2011

Targeting PKC in human pancreatic neuroendocrine tumor cells

Mole D , Gagliano T , Gentilin E , Bondanelli M , Tagliati F , degli Uberti E , Zatelli M C

The currently curative therapy for pancreatic endocrine tumours (PET), accounting for <3% of pancreatic tumors, is complete surgical resection, which is achieved in the minority of cases. Most tumors are diagnosed in a late stage, especially in endocrine-inactive forms, indicating the need for further medical therapy. The serine–threonine protein kinase C (PKC) family plays central regulatory roles in several cellular processes, including cell proliferation. PKC signa...

ea0022p764 | Thyroid | ECE2010

Evaluation of PKC isoforms expression in thyroid cells lines and effects of a PKC beta II selective inhibitor

Mole Daniela , Minoia Mariella , Tagliati Federico , Zatelli Maria Chiara , degli Uberti Ettor`e C

Protein kinase C (PKC) is a key enzyme which regulates proliferation, apoptosis and differentiation, representing a pharmacological target for tumor therapy. PKC is a serin/threonin kinase involved in the control of neoplastic transformation, carcinogenesis, neoplastic invasion, chemoresistance. The role of PKC depends on the tissue and on the specific isoform, among the 11 identified so far. In particular, PKC beta II inhibits cell functions, while PKC delta has a protective ...

ea0020p209 | Endocrine tumours and neoplasia | ECE2009

R171Q MEN1 polymorphism in patients presenting with hyperparathyroidism

Zatelli Maria Chiara , Filieri Carlo , Tagliati Federico , Ambrosio Maria Rosaria , degli Uberti Ettore

The change of aminoacid Arginine (CGG) to Glutamine (CAG) at position 171 (R171Q) in the MEN1 gene has been occasionally reported in MEN1 carriers, but also in 1.4 to 5% subjects among the general population, therefore it is still unclear whether it might represent a polymorphism and/or it has a role in tumourigenesis. The aim of our study was to evaluate the presence of the R171Q polymorphism in patients with MEN1-related states presenting for MEN1 genetic screening. F...

ea0016p316 | Endocrine tumours | ECE2008

Effects of pasireotide on bronchial carcinoids in primary culture

Zatelli Maria Chiara , Tagliati Federico , Luchin Andrea , Bondanelli Marta , Rea Federico , degli Uberti Ettore

Bronchopulmonary endocrine tumors represent 25–30% of lung neoplasms. Surgery provides good survival for differentiated tumors (typical and atypical carcinoids), but is not useful for aggressive poorly differentiated forms. Somatostatin (SRIF) analogs can be used as medical therapy, prolonging patient survival. However, the compounds employed so far did not display antiproliferative effects. Recently, a new stable SRIF analog, pasireotide (SOM230), which activates SSTR1, ...

ea0011p461 | Endocrine tumours and neoplasia | ECE2006

Role of complex Cdk4/Cyclin D1 in somatostatin subtype 2 receptor-mediated inhibition of cell proliferation of a medullary thyroid carcinoma cell line in vitro

Tagliati F , Zatelli MC , Bottoni A , Piccin D , Luchin A , Culler MD , degli Uberti EC

Somatostatin (SRIH) inhibits cell proliferation by interacting with five distinct SRIH receptor subtypes (SSTR) by several pathways in many tissues. We previously demonstrated that SRIH, by activating SHP-1, inhibits cell proliferation of the human Medullary Thyroid Carcinoma (MTC) cell line, TT, which expresses all SSTR. However, the effects of SRIH on cell cycle proteins have not been investigated, so far. We therefore investigated the effects of SRIH and of a selective SSTR...